rate between statin and placebo arms in published outcomes studies (4S, CARE, LIPID, HPS), was performed for major clinical endpoints. A model was developed to estimate LDL-C reductions using alternative baseline LDL-C values and the weighted mean difference (WMD) from the meta-analysis. These were combined with results from regression analyses to calculate percentage reduction in cardiovascular events and impact estimated for a population of 100,000. The model was also run using the 95% confidence intervals from the meta-analysis. RESULTS: Meta-analysis demonstrated a significant reduction in LDL-C in favour of rosuvastatin 40 mg (WMD -5.26%, 95% CI: -6.08% to -4.43%; p < 0.00001). There was no significant heterogeneity identified in the meta-analysis (p = 0.42) with low inconsistency in trial results (I2 = 2.1%). Regression analyses showed good correlation (R2 > 0.65) between LDL-C reduction and percentage difference in event rates for coronary death, major coronary event, non-fatal myocardial infarction (MI) and revascularisations (CABG and PCTA). Simulations using alternative LDL-C distributions with means varying from 3.40-7.56 mmol/L generated LDL-C reductions of 1.68-3.78 and 1.85-4.18 for rosuvastatin 20 mg and 40 mg, respectively. These values translated into the following reductions depending on the mean of the distribution: 0.33%-0.74% coronary deaths; 0.72%-1.62% major coronary events; 0.52%-1.17% non-fatal MIs; 0.59%-1.32% revascularisation procedures. Based on a population of 100,000, the incremental benefit of rosuvastatin 40 mg over 20 mg resulted in the prevention of 329-742 coronary deaths, 721-1,624 major coronary events, 517-1,165 non-fatal MIs and 586-1,321 revascularisation procedures. CONCLUSION: Rosuvastatin 40 mg reduces LDL-C significantly more than 20 mg. Modelled outcomes suggest this may translate into substantially fewer cardiovascular-related events. OBJECTIVES: With the lowering of the recommended cholesterol levels in Europe, use of lipid lowering drugs has become a more important clinical option. The study aim was to determine total cholesterol levels by type of lipid lowering therapy in the primary care setting in France, Italy and the UK. METHODS:
mean LDL-C reduction and difference in event rate between statin and placebo arms in published outcomes studies (4S, CARE, LIPID, HPS), was performed for major clinical endpoints. A model was developed to estimate LDL-C reductions using alternative baseline LDL-C values and the weighted mean difference (WMD) from the meta-analysis. These were combined with results from regression analyses to calculate percentage reduction in cardiovascular events and impact estimated for a population of 100,000. The model was also run using the 95% confidence intervals from the meta-analysis. RESULTS: Meta-analysis demonstrated a significant reduction in LDL-C in favour of rosuvastatin 40 mg (WMD -5.26%, 95% CI: -6.08% to -4.43%; p < 0.00001). There was no significant heterogeneity identified in the meta-analysis (p = 0.42) with low inconsistency in trial results (I2 = 2.1%). Regression analyses showed good correlation (R2 > 0.65) between LDL-C reduction and percentage difference in event rates for coronary death, major coronary event, non-fatal myocardial infarction (MI) and revascularisations (CABG and PCTA). Simulations using alternative LDL-C distributions with means varying from 3.40-7.56 mmol/L generated LDL-C reductions of 1.68-3.78 and 1.85-4.18 for rosuvastatin 20 mg and 40 mg, respectively. These values translated into the following reductions depending on the mean of the distribution: 0.33%-0.74% coronary deaths; 0.72%-1.62% major coronary events; 0.52%-1.17% non-fatal MIs; 0.59%-1.32% revascularisation procedures. Based on a population of 100,000, the incremental benefit of rosuvastatin 40 mg over 20 mg resulted in the prevention of 329-742 coronary deaths, 721-1,624 major coronary events, 517-1,165 non-fatal MIs and 586-1,321 revascularisation procedures. CONCLUSION: Rosuvastatin 40 mg reduces LDL-C significantly more than 20 mg. Modelled outcomes suggest this may translate into substantially fewer cardiovascular-related events.
PCV7 DIFFERENCES IN CHOLESTEROL LEVELS BETWEEN STATIN AND FIBRATE TREATED PATIENTS IN FRENCH, ITALIAN AND UNITED KINGDOM PRIMARY CARE
Blak BT 1 , Maguire A 1 , Schwalm MS 2 1 EPIC, London, UK, 2 Cededim Strategic Data, Paris, France OBJECTIVES: With the lowering of the recommended cholesterol levels in Europe, use of lipid lowering drugs has become a more important clinical option. The study aim was to determine total cholesterol levels by type of lipid lowering therapy in the primary care setting in France, Italy and the UK. METHODS:
The study populations were identified from the THALES (France, Italy) and The Health Improvement Network "THIN" (UK) primary care databases. Patients were included if they received a fibrate or statin prescription in the first 6 months of 2005 (index), had a prescription at least 6 months before index and had a valid cholesterol record during the 12 months after index. To account for differing cholesterol reporting habits, analyses were restricted to general practitioners with cholesterol reporting rate >50%. Multivariate linear regression was applied to compare the effect of drug type on cholesterol level by country. RESULTS: The rates of statin use were 71%, 88% and 97% for France, Italy and the UK respectively. In France, the median cholesterol was 5.2 mmol/L among statin users (n = 22674; mean age = 65; male = 57%) compared to 5.3 mmol/L among fibrate users (n = 9283; age = 66; male = 46%). In Italy, the median cholesterol was 5.2 mmol/L among statin users (n = 4822; age = 67; male = 48%) compared to 5.4 mmol/L among fibrates users (n = 641; age = 65; male = 56%). In the UK, median cholesterol was 4.4 mmol/L among statin users (n = 113252; age = 67; male = 55%) compared to 5.1 mmol/L among fibrate users (n = 3626; age = 65; male = 49%). For each country, statin therapy was associated (p < 0.001) with lower median cholesterol level after controlling for age, gender, diabetes and coronary heart disease. CONCLUSION: The use of statins in primary care was dominant in all countries studied, although prescribing habits varied. Cholesterol levels were lower among statin users than fibrate users and this difference was greatest in the UK.
PCV8 EPROSARTAN VERSUS OTHER ANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS
Kaczor M, Wojcik R, Walczak J, Nogas G Arcana Institute, Cracow, Poland OBJECTIVES: To compare the clinical effectiveness of eprosartan and irbesartan, losartan, telmisartan and valsartan in patients with hypertension. METHODS: The clinical effectiveness analysis in accordance with the Cochrane Collaboration guidelines were performed. In the absence (or lack of sufficient data) of RCT making head-to-head comparisons of eprosartan vs other angiotensin-receptor blockers meta-analysis based on an indirect comparison was performed, using placebo as the common comparator (Bucher method). RESULTS: Eprosartan vs losartan-Because of the lack of sufficient data, indirect analysis was performed. Compared drugs was comparable in terms of efficacy. In the safety analysis no significant differences were observed between groups except withdrawal due to adverse events which was more common in losartan group OR 0.46 (95%CI: 0.23; 0.96). Eprosartan vs telmisartan-Indirect analysis showed that there is now statistically significantly difference in change systolic pressure. There was statistically significant difference between groups on favors telmisartan in achieving clinical response OR 0.42 (95%CI: 0.23; 0.76). Safety of both interventions was the same. Eprosartan vs valsartan or irbesartan: Analysis based on indirect evidence showed no significant differences between the groups in terms of efficacy (change in systolic and diastolic pressure, response to treatment).The incidence of adverse events was similar in compared groups. CONCLUSION: Analysis suggests that eprosartan has comparable efficacy to losartan, valsartan, irbesartan. Telmisartan is more effective compared with eprosartan for treatment of patients with hypertension. Safety of interventions is comparable. However, results based on indirect evidence need to be viewed cautiously.
PCV9 DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING
Heintjes EM 1 , Penning-van Beest FJA 1 , Johansson S 2 , Stalenhoef AF 3 , Herings RMC 1 1 PHARMO Institute, Utrecht, The Netherlands, 2 AstraZeneca R&D, Mölndal, Sweden, 3 Radboud University Medical Centre, Nijmegen, Gelderland, The Netherlands OBJECTIVES: This study compares the differences in incidences of hospitalisations for cardiovascular events between users of selected statins. METHODS: New statin users between January 1, 2000 and September 30, 2005 were extracted from the PHARMO database (population 3 million) and followed for maximally two years after start of statin use, up to December 31, 2005. Incidences of hospitalisations for fatal and non-fatal cardiovascular disease (CVD) in general (including ischemic heart Abstracts A407
